TerminatedNCT00288275
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
Studying Malignant non-epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Precision Therapeutics
- Principal Investigator
- Thomas J Rutherford, MDYale University
- Enrollment
- 256 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2004 – 2012
Study locations (30)
- University of California, Irvine, California, United States
- Kaiser Permanente, Los Angeles, California, United States
- Yale University Medical Center, New Haven, Connecticut, United States
- Florida Gynecologic Oncology, Fort Myers, Florida, United States
- St. Vincents Medical Center, Jacksonville, Florida, United States
- The Florida Hospital, Orlando, Florida, United States
- Women's Cancer Associates, St. Petersburg, Florida, United States
- Atlanta Medical Center, Atlanta, Georgia, United States
- Southeastern Gynecologic Oncology Riverdale, Riverdale, Georgia, United States
- Northwestern University/Prentice Women's Hospital, Chicago, Illinois, United States
- Rush University, Chicago, Illinois, United States
- St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States
- St. Elizabeth Medical Center, Edgewood, Kentucky, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00288275 on ClinicalTrials.govOther trials for Malignant non-epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRadiopharm Theranostics, Ltd
- RECRUITINGPHASE1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics
- RECRUITINGPHASE1NCT06238479A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsEli Lilly and Company
- ACTIVE NOT RECRUITINGPHASE2NCT06169124Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05872204Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT04644289WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCAGO Research GmbH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx Limited
See all trials for Malignant non-epithelial tumor of ovary →